Equities research analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO - Get Free Report) in a research note issued on Tuesday. The brokerage set a "strong-buy" rating on the medical research company's stock.
Global Cord Blood Stock Up 42.9 %
NYSE:CO traded up $0.45 on Tuesday, reaching $1.50. 14,458 shares of the company's stock were exchanged, compared to its average volume of 216,519. The business has a fifty day moving average of $1.32 and a 200-day moving average of $1.40. Global Cord Blood has a 52-week low of $2.03 and a 52-week high of $5.50. The firm has a market capitalization of $182.33 million, a price-to-earnings ratio of 2.34 and a beta of 0.16.
Global Cord Blood Company Profile
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Stories
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
